DEFR14A: BioSig Withdraws Streamex Acquisition Vote

BioSig Technologies, Inc. has withdrawn the proposal for stockholder approval of share issuance related to its Streamex acquisition from the upcoming Special Meeting.

Summary

• This document is Amendment No. 2 to the definitive proxy statement of BioSig Technologies, Inc., originally filed on August 4, 2025, and amended on August 15, 2025.
• The amendment withdraws the Acquisition Proposal (Proposal No. 1) from stockholder consideration at the Special Meeting scheduled for September 5, 2025.
• Proposal No. 1 sought stockholder approval for the issuance of approximately 109,070,079 shares of common stock and one share of Super Voting Preferred Stock for the consummated acquisition of Streamex Exchange Corporation.
• The Board of Directors determined not to proceed with this specific proposal at the Special Meeting.
• The company intends to obtain shareholder approval for the Acquisition Proposal as soon as reasonably practicable.
• All other proposals included in the original proxy statement will proceed to a vote at the Special Meeting.
• Existing proxy cards and voting instructions remain valid, with votes pertaining to Proposal No. 1 to be disregarded.

Sentiment

Score: 4

Explanation: The withdrawal of a key acquisition-related proposal from the upcoming shareholder meeting introduces uncertainty and a delay in formalizing the share issuance. While the company states intent to seek approval later, the immediate deferral is a negative signal for timely execution and could impact investor confidence.

Positives

• The company still intends to obtain shareholder approval for the Streamex acquisition's share issuance as soon as reasonably practicable, indicating the underlying acquisition is not necessarily cancelled.

Negatives

• The formal stockholder approval for the share issuance related to the Streamex acquisition is delayed.
• Uncertainty exists regarding the specific timeline for when the company will seek shareholder approval for the Acquisition Proposal.

Risks

• Potential for prolonged uncertainty regarding the final shareholder approval of the share issuance for the Streamex acquisition.
• Risk of investor confusion or misinterpretation due to the withdrawal of a key proposal from the Special Meeting.

Future Outlook

The company intends to obtain shareholder approval of the Acquisition Proposal as soon as reasonably practicable, indicating a future vote on the share issuance related to the Streamex acquisition.

Management Comments

• The Board of Directors has determined not to proceed with the Acquisition Proposal (Proposal No. 1) at the Special Meeting.

Industry Context

This filing details a specific corporate governance action by BioSig Technologies, Inc. regarding a previously announced acquisition, rather not reflecting broader industry trends. The withdrawal of a proposal for shareholder vote can sometimes signal internal strategic adjustments or a need for further clarification before seeking formal approval.

Corporate Governance

Stakeholder Impact

• Shareholders: Experience a delay in voting on a significant share issuance related to an acquisition, potentially leading to uncertainty regarding the company's capital structure and future dilution.
• Streamex Exchange Corporation: While the acquisition is stated as 'consummated,' the delay in formal shareholder approval for the share issuance might affect the finalization of certain financial or structural aspects of the deal.

Next Steps

• The company intends to obtain shareholder approval of the Acquisition Proposal as soon as reasonably practicable.
• Other proposals included in the Proxy Statement will proceed to a vote at the Special Meeting on September 5, 2025.

Key Dates

Recommendation

The withdrawal of the Acquisition Proposal from the Special Meeting introduces an element of uncertainty and delay regarding the formal shareholder approval for a significant share issuance. While the company intends to seek approval later, the immediate deferral could lead to short-term investor apprehension. However, the acquisition itself is stated as 'consummated,' suggesting the underlying strategic move is still in place. Investors should hold and monitor for further announcements regarding the rescheduled vote and any additional context for the withdrawal.

Keywords

BioSig Technologies, Streamex Exchange Corporation, SEC filing, proxy statement, acquisition, shareholder vote, stock issuance, corporate governance, DEFR14A